CL2012000524A1 - Anticuerpo humanizado que se une a cdcp1 humana útil en el tratamiento del cáncer; composición farmacéutica; ácido nucleico, vector de expresión y célula huésped que lo comprende; y método para producir el anticuerpo. - Google Patents
Anticuerpo humanizado que se une a cdcp1 humana útil en el tratamiento del cáncer; composición farmacéutica; ácido nucleico, vector de expresión y célula huésped que lo comprende; y método para producir el anticuerpo.Info
- Publication number
- CL2012000524A1 CL2012000524A1 CL2012000524A CL2012000524A CL2012000524A1 CL 2012000524 A1 CL2012000524 A1 CL 2012000524A1 CL 2012000524 A CL2012000524 A CL 2012000524A CL 2012000524 A CL2012000524 A CL 2012000524A CL 2012000524 A1 CL2012000524 A1 CL 2012000524A1
- Authority
- CL
- Chile
- Prior art keywords
- antibody
- binds
- producing
- nucleic acid
- host cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
Anticuerpo que se une a CDCP1 humana; ácido nucleico, vector de expresión y célula huésped que lo comprende; método para producir un anticuerpo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09011046 | 2009-08-28 | ||
EP10000972 | 2010-02-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2012000524A1 true CL2012000524A1 (es) | 2012-08-17 |
Family
ID=43086176
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2012000524A CL2012000524A1 (es) | 2009-08-28 | 2012-02-28 | Anticuerpo humanizado que se une a cdcp1 humana útil en el tratamiento del cáncer; composición farmacéutica; ácido nucleico, vector de expresión y célula huésped que lo comprende; y método para producir el anticuerpo. |
Country Status (24)
Country | Link |
---|---|
US (2) | US8394928B2 (es) |
EP (1) | EP2470567A1 (es) |
JP (1) | JP5647687B2 (es) |
KR (1) | KR101495407B1 (es) |
CN (1) | CN102482357B (es) |
AR (1) | AR077973A1 (es) |
AU (1) | AU2010288879A1 (es) |
BR (1) | BR112012004221A2 (es) |
CA (1) | CA2770161A1 (es) |
CL (1) | CL2012000524A1 (es) |
CO (1) | CO6511201A2 (es) |
CR (1) | CR20120038A (es) |
EC (1) | ECSP12011701A (es) |
HK (1) | HK1167412A1 (es) |
IL (1) | IL217919A0 (es) |
MA (1) | MA33537B1 (es) |
MX (1) | MX2012002458A (es) |
NZ (1) | NZ597664A (es) |
PE (1) | PE20121063A1 (es) |
RU (1) | RU2571207C2 (es) |
SG (1) | SG178886A1 (es) |
TW (1) | TWI412375B (es) |
UA (1) | UA106890C2 (es) |
WO (1) | WO2011023389A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI412375B (zh) * | 2009-08-28 | 2013-10-21 | Roche Glycart Ag | 人類化抗cdcp1抗體 |
TW201113037A (en) * | 2009-08-28 | 2011-04-16 | Hoffmann La Roche | Antibodies against CDCP1 for the treatment of cancer |
WO2012107416A2 (en) | 2011-02-10 | 2012-08-16 | Roche Glycart Ag | Improved immunotherapy |
TR201816437T4 (tr) | 2012-08-07 | 2018-11-21 | Roche Glycart Ag | Azalmış ve artmış efektör fonksiyonuna sahip olacak şekilde tasarlanmış iki antikor içeren bileşim. |
PT2928923T (pt) | 2012-12-10 | 2020-03-27 | Biogen Ma Inc | Anticorpos antígenos 2 de células dendríticas anti-sangue e os seus usos |
WO2014172448A2 (en) * | 2013-04-17 | 2014-10-23 | Anaptysbio, Inc. | Antibodies directed against activin receptor type ii (actrii) |
WO2015082446A1 (en) | 2013-12-02 | 2015-06-11 | F. Hoffmann-La Roche Ag | Treatment of cancer using an anti-cdcp1 antibody and a taxane |
JP2017505124A (ja) | 2014-01-24 | 2017-02-16 | ザ ヘンリー エム. ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド | ヘンドラ及びニパウイルスのf糖タンパク質に対する抗体 |
WO2015200522A2 (en) * | 2014-06-25 | 2015-12-30 | Integrated Biotherapeutics, Inc. | Monoclonal antibodies directed against envelope glycoproteins from multiple filovirus species |
CA3047115A1 (en) * | 2016-12-16 | 2018-06-21 | Bluefin Biomedicine, Inc. | Anti-cub domain-containing protein 1 (cdcp1) antibodies, antibody drug conjugates, and methods of use thereof |
US10928391B2 (en) * | 2017-06-06 | 2021-02-23 | The Cleveland Clinic Foundation | CD318 as a marker for, and CD318 inhibition as a treatment for, autoimmune disease |
WO2019084319A1 (en) | 2017-10-25 | 2019-05-02 | The Regents Of The University Of California | ANTIBODIES AGAINST CDCP1 FOR THE TREATMENT AND DETECTION OF CANCER |
CN113382750A (zh) * | 2018-11-09 | 2021-09-10 | 贝斯以色列女执事医疗中心 | Cdcp1靶向疗法 |
JP2022523746A (ja) * | 2019-02-01 | 2022-04-26 | フォンダツィオーネ・ペア・リスチチュート・オンコロジコ・ディ・リチェルカ・(イオエッレ) | 去勢抵抗性前立腺がんを処置する方法 |
US20230050380A1 (en) | 2019-12-27 | 2023-02-16 | Chiome Bioscience Inc. | Anti-cdcp1 antibody |
CN117264055A (zh) * | 2022-06-14 | 2023-12-22 | 上海恒润达生生物科技股份有限公司 | 一种特异性结合人cd318的vhh抗体或其抗原结合片段及其制备方法和应用 |
WO2023246701A1 (zh) * | 2022-06-20 | 2023-12-28 | 四川汇宇制药股份有限公司 | 一种抗体及其用途 |
WO2024013723A1 (en) | 2022-07-15 | 2024-01-18 | Pheon Therapeutics Ltd | Antibody drug conjugates that bind cdcp1 and uses thereof |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
EP0938506B1 (en) * | 1996-07-16 | 2003-11-05 | Plückthun, Andreas, Prof. Dr. | Immunoglobulin superfamily domains and fragments with increased solubility |
DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
ES2420835T3 (es) | 1999-04-09 | 2013-08-27 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de las moléculas inmunofuncionales |
FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
CN1329061A (zh) | 2000-06-19 | 2002-01-02 | 上海博德基因开发有限公司 | 一种新的多肽——人g蛋白亚基9.46和编码这种多肽的多核苷酸 |
EP1301533A1 (de) | 2000-07-07 | 2003-04-16 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Tumorassoziiertes antigen (b345), gekennzeichnet durch eine aminosäuresequenz wie in seq. id. no. 4 |
NZ592087A (en) * | 2001-08-03 | 2012-11-30 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
JP2005532253A (ja) | 2001-10-25 | 2005-10-27 | ジェネンテック・インコーポレーテッド | 糖タンパク質組成物 |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
DE10242146A1 (de) * | 2002-09-04 | 2004-03-18 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Antikörper zur Identifizierung und/oder Isolierung von hämatopoetischen Stammzellen |
PL222222B1 (pl) | 2003-01-22 | 2016-07-29 | Glycart Biotechnology Ag | Sposób wytwarzania polipeptydu |
BRPI0407680A (pt) | 2003-02-19 | 2006-03-01 | Novartis Ag | métodos para diagnóstico de cáncer e diminuição de metástase por células cancerosas |
CA2534077A1 (en) | 2003-07-29 | 2005-02-10 | Morphotek Inc. | Antibodies and methods for generating genetically altered antibodies with enhanced effector function |
CA2536408A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
EP1663306A2 (en) | 2003-09-05 | 2006-06-07 | Genentech, Inc. | Antibodies with altered effector functions |
GB0324656D0 (en) | 2003-10-22 | 2003-11-26 | Celltech R&D Ltd | A protein involved in ovarian cancer |
WO2005044859A2 (en) | 2003-11-05 | 2005-05-19 | Glycart Biotechnology Ag | Cd20 antibodies with increased fc receptor binding affinity and effector function |
US20080008719A1 (en) | 2004-07-10 | 2008-01-10 | Bowdish Katherine S | Methods and compositions for the treatment of prostate cancer |
US7632497B2 (en) | 2004-11-10 | 2009-12-15 | Macrogenics, Inc. | Engineering Fc Antibody regions to confer effector function |
TW200720289A (en) | 2005-04-01 | 2007-06-01 | Hoffmann La Roche | Antibodies against CCR5 and uses thereof |
WO2006114700A2 (en) | 2005-04-26 | 2006-11-02 | Bioren, Inc. | Method of producing human igg antibodies with enhanced effector functions |
WO2006116260A2 (en) | 2005-04-26 | 2006-11-02 | Medimmune, Inc. | Modulation of antibody effector function by hinge domain engineering |
WO2007005502A2 (en) | 2005-06-30 | 2007-01-11 | Applera Corporation | Methods and compositions for treating diseases targeting cdcp1 |
SG192479A1 (en) | 2005-08-26 | 2013-08-30 | Roche Glycart Ag | Modified antigen binding molecules with altered cell signaling activity |
JP2007112734A (ja) * | 2005-10-19 | 2007-05-10 | Chugai Pharmaceut Co Ltd | 抗cdcp1抗体を含有する癌細胞増殖抑制剤 |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
TWI412375B (zh) * | 2009-08-28 | 2013-10-21 | Roche Glycart Ag | 人類化抗cdcp1抗體 |
-
2010
- 2010-08-25 TW TW099128526A patent/TWI412375B/zh not_active IP Right Cessation
- 2010-08-26 NZ NZ597664A patent/NZ597664A/xx not_active IP Right Cessation
- 2010-08-26 CN CN201080037452.7A patent/CN102482357B/zh not_active Expired - Fee Related
- 2010-08-26 KR KR1020127007820A patent/KR101495407B1/ko not_active IP Right Cessation
- 2010-08-26 RU RU2012111708/10A patent/RU2571207C2/ru not_active IP Right Cessation
- 2010-08-26 MX MX2012002458A patent/MX2012002458A/es active IP Right Grant
- 2010-08-26 WO PCT/EP2010/005244 patent/WO2011023389A1/en active Application Filing
- 2010-08-26 BR BR112012004221A patent/BR112012004221A2/pt not_active IP Right Cessation
- 2010-08-26 CA CA2770161A patent/CA2770161A1/en not_active Abandoned
- 2010-08-26 PE PE2012000273A patent/PE20121063A1/es not_active Application Discontinuation
- 2010-08-26 US US12/868,845 patent/US8394928B2/en not_active Expired - Fee Related
- 2010-08-26 JP JP2012525932A patent/JP5647687B2/ja not_active Expired - Fee Related
- 2010-08-26 SG SG2012013397A patent/SG178886A1/en unknown
- 2010-08-26 EP EP10748062A patent/EP2470567A1/en not_active Withdrawn
- 2010-08-26 AU AU2010288879A patent/AU2010288879A1/en not_active Abandoned
- 2010-08-26 UA UAA201203442A patent/UA106890C2/uk unknown
- 2010-08-26 AR ARP100103121A patent/AR077973A1/es unknown
-
2012
- 2012-01-20 CR CR20120038A patent/CR20120038A/es unknown
- 2012-02-02 IL IL217919A patent/IL217919A0/en unknown
- 2012-02-27 MA MA34651A patent/MA33537B1/fr unknown
- 2012-02-28 EC ECSP12011701 patent/ECSP12011701A/es unknown
- 2012-02-28 CL CL2012000524A patent/CL2012000524A1/es unknown
- 2012-02-29 CO CO12035757A patent/CO6511201A2/es active IP Right Grant
- 2012-08-20 HK HK12108145.3A patent/HK1167412A1/xx not_active IP Right Cessation
- 2012-12-20 US US13/721,553 patent/US9346886B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CR20120038A (es) | 2012-04-18 |
EP2470567A1 (en) | 2012-07-04 |
RU2571207C2 (ru) | 2015-12-20 |
AU2010288879A1 (en) | 2012-02-02 |
RU2012111708A (ru) | 2013-10-10 |
MX2012002458A (es) | 2012-03-14 |
JP5647687B2 (ja) | 2015-01-07 |
UA106890C2 (uk) | 2014-10-27 |
US9346886B2 (en) | 2016-05-24 |
MA33537B1 (fr) | 2012-08-01 |
SG178886A1 (en) | 2012-04-27 |
ECSP12011701A (es) | 2012-03-30 |
BR112012004221A2 (pt) | 2016-11-29 |
CN102482357B (zh) | 2014-06-11 |
US8394928B2 (en) | 2013-03-12 |
AR077973A1 (es) | 2011-10-05 |
CA2770161A1 (en) | 2011-03-03 |
KR20120089658A (ko) | 2012-08-13 |
US20110052582A1 (en) | 2011-03-03 |
TWI412375B (zh) | 2013-10-21 |
WO2011023389A1 (en) | 2011-03-03 |
IL217919A0 (en) | 2012-03-29 |
HK1167412A1 (en) | 2012-11-30 |
JP2013502904A (ja) | 2013-01-31 |
NZ597664A (en) | 2013-03-28 |
CN102482357A (zh) | 2012-05-30 |
KR101495407B1 (ko) | 2015-02-24 |
CO6511201A2 (es) | 2012-08-31 |
PE20121063A1 (es) | 2012-08-09 |
TW201110983A (en) | 2011-04-01 |
US20130209455A1 (en) | 2013-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2012000524A1 (es) | Anticuerpo humanizado que se une a cdcp1 humana útil en el tratamiento del cáncer; composición farmacéutica; ácido nucleico, vector de expresión y célula huésped que lo comprende; y método para producir el anticuerpo. | |
CY1123079T1 (el) | Τροποποιημενα πολυπεπτιδια γiα ικριωματα διειδικων αντισωματων | |
PE20170772A1 (es) | Anticuerpo monoclonal anti-ctla4 o su fragmento de union a antigeno, una composicion farmaceutica y uso | |
PE20180484A1 (es) | Moleculas biespecificas de union a antigeno activadoras de celulas t | |
CO2018000882A2 (es) | Constructos de anticuerpo para flt3 y cd3 | |
PE20170704A1 (es) | Agente terapeutico que induce citotoxicidad | |
CL2016002116A1 (es) | Anticuerpos anti-fap y métodos de utilización (divisional sol. n°369-13). | |
CO2018000887A2 (es) | Constructos de anticuerpo biespecificos que se unen a egfrviii y cd3 | |
PE20161327A1 (es) | Proteinas de enlace al antigeno il-23 humana | |
AR090903A1 (es) | Anticuerpos e inmunoconjugados anti-pmel17 | |
MX2015012122A (es) | Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes. | |
CL2013003552A1 (es) | Anticuerpo aislado que se une a la proteina 3 humana de tipo angiopoyetina (hangptl3); molécula de ácido nucleico; vector de expresión, célula hospedera; método de producción de un anticuerpo. | |
TN2015000396A1 (en) | Antibody drug conjugates | |
CL2014001730A1 (es) | Anticuerpo anti-epirregulina humanizado; vector; celula huesped; metodo de produccion; composicion farmaceutica que lo comprende; y agente terapeutico contra el cancer que lo comprende. | |
AR087608A1 (es) | Moleculas biespecificas de union a antigeno activadoras de celulas t | |
CL2012000914A1 (es) | Anticuerpos monoclonales que se unen especificamente a la region c-terminal de progastrina. uso para la preparacion de un medicamento util en el tratamiento de cancer colorectal. | |
AR094896A1 (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t | |
CL2008002444A1 (es) | Anticuerpo o fragmento del mismo que se une a la proteina c-fms humana; molecula de acido nucleico que la codifica; vector y celula huesped; metodo de elaboracion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir una condicion asociada con c-fms en un paciente. | |
EA201492101A1 (ru) | Антитела против fcrn | |
UA116873C2 (uk) | Антитіло, яке зв'язується з ox40 | |
PE20181054A1 (es) | Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion | |
AR077334A1 (es) | Anticuerpos muc1 antimucina | |
CL2011002756A1 (es) | Anticuerpo que se enlaza a la proteina del complemento c3b humana o de cinomolgo; composicion farmaceutica, acido nucleico, vector y celula huesped que comprenden dicho anticuerpo; uso para tratar degeneracion macular relacionada con la edad. | |
CL2016000438A1 (es) | Anticuerpos humanizados que se unen específicamente al receptor del factor estimulante de colonias 1 (csf-1r); ácidos nucleicos; vectores de expresión, células huéspedes; procesos de producción; composiciones farmacéuticas; usos y métodos de tratamiento terapéutico para el tratamiento del cáncer y de la enfermedad fibrótica | |
BR112014026740A8 (pt) | anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo |